July 2, 2024

Stephan Jackman
Chief Executive Officer
Alzamend Neuro, Inc.
3480 Peachtree Road NE, Second Floor, Suite 103
Atlanta, GA 30326

       Re: Alzamend Neuro, Inc.
           Amendment No. 1 to Registration Statement on Form S-1
           Filed June 26, 2024
           File No. 333-279920
Dear Stephan Jackman:

     We have conducted a limited review of your registration statement and have 
the following
comment.

       Please respond to this letter by amending your registration statement 
and providing the
requested information. If you do not believe a comment applies to your facts 
and circumstances
or do not believe an amendment is appropriate, please tell us why in your 
response.

       After reviewing any amendment to your registration statement and the 
information you
provide in response to this letter, we may have additional comments.

Amendment No. 1 to Registration Statement on Form S-1
Plan of Distribution, page 14

1.     We note your response to prior comment 2. Please include the information 
provided in
       your response letter in the registration statement. Specifically, please 
revise this section to
       include disclosure that 1) any broker-dealers or agents that may become 
involved in
       selling the registered shares offered under this prospectus may be 
deemed to be
          underwriters    within the meaning of the Securities Act in 
connection with such sales,
       and 2) any broker-dealers or agents that are deemed to be underwriters 
may not sell
       registered shares offered under this prospectus unless and until Company 
sets forth the
       names of the underwriters and the material details of their underwriting 
arrangements in
       a replacement prospectus included in a post-effective amendment to the 
registration
       statement of which this prospectus is a part.
       We remind you that the company and its management are responsible for 
the accuracy and
 July 2, 2024
Page 2

adequacy of their disclosures, notwithstanding any review, comments, action or 
absence of action
by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please 
allow adequate
time for us to review any amendment prior to the requested effective date of 
the registration
statement.

       Please contact Lauren Hamill at 303-844-1008 or Chris Edwards at 
202-551-6761 with
any other questions.



                                                           Sincerely,

                                                           Division of 
Corporation Finance
                                                           Office of Life 
Sciences
cc:   Henry Nisser